Biokine
Building 13A
Weizmann Science Park<br>P.O. Box 2213
Rehovot
76120
Tel: 972-8-9301015
Fax: 972-8-9301016
Website: http://www.biokine.com/
Email: orly.eizenberg@biokine.com
4 articles about Biokine
-
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
10/3/2018
Transaction increases BioLineRx's stake by 20%, to 80%, ahead of numerous potential value-creating milestones
-
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
8/7/2018
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from the lead-in period of the GENESIS trial.
-
Biokine Awarded FDA Orphan Drug Designation for Mobilization of Stem Cells in Cancer Patients
7/25/2012
-
Biokine Announces $1.2 Million Research Grant by the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of Israel
3/18/2009